ClinicalTrials.gg
Active, not recruitingNCT04538664PAPILLONUpdated Nov 3, 2026Results posted

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

A Phase 3 interventional study of Amivantamab and Pemetrexed in Carcinoma, Non-Small-Cell Lung, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 232 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Updated Oct 29, 2026Study completion moved1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
308
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
33rd of 223
308 · median 64
Started
2020
with 12 others
Phase 3
44 of 227
4 open now
Primary completion
2023-05
later than 1 of 31 live
Registered
195th of 227
by date

Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 33rd largest by enrollment of the 223 interventional ones that give a count, is one of 13 that started in 2020, is one of 44 in phase 3, reaches primary completion later than 1 of the 31 other live ones, and was the 195th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • EGFR Exon20ins Mutation
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have or cytologically confirmed, locally advanced or , nonsquamous non-small cell lung cancer (NSCLC) with documented primary epidermal growth factor receptor (EGFR) Exon 20ins activating mutation
  • Participant must have according to (RECIST) v1.1.
  • Participant must have (ECOG) performance status 0 or 1
  • Participant must agree to genetic characterization of tumor status through the required pretreatment tumor (or submission of equivalent archival material), as well as baseline and periodic blood samples for analysis of tumor mutations in the bloodstream
  • A female participant of must have a negative serum or urine test at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study

Exclusion criteria

Exclusion Criteria:

  • Participant has evidence of synchronous NSCLC disease (as suggested by genetic characterization or radiographic appearance)
  • Participant has untreated (a participant with definitively, locally treated who is clinically stable, asymptomatic, and off treatment for at least 2 weeks prior to randomization is eligible)
  • Participant has history of spinal cord compression that has not been treated definitively with surgery or radiation
  • Participant has a medical history of interstitial lung disease (ILD), including drug-induced ILD, or radiation pneumonitis
  • Participant has a to the use of carboplatin or pemetrexed (refer to local prescribing information for each agent). Participant has a history of to, or cannot take, vitamin B12 or folic acid
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
308 participants (actual)

Study arms

  • Experimental
    Arm A: Amivantamab + Chemotherapy

    Participants will receive pemetrexed 500 milligram per meter square (mg/m\^2) intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin area under the concentration-time curve 5 milligram per milliliter (mg/mL) per minute (AUC 5) will be administered as IV infusion on Day 1 of each 21 day cycle, for up to 4 cycles. Participants will receive amivantamab 1400 mg (1750 mg if body weight is \>=80 kilogram \[kg\]) by IV infusion once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is \>=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will continue to receive the amivantamab plus chemotherapy in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment.

    Drug: Amivantamab · Drug: Pemetrexed · Drug: Carboplatin

  • Experimental
    Arm B: Chemotherapy Alone

    Participants will receive pemetrexed 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin AUC 5 IV infusion will be administered on Day 1 of each 21-day cycle for up to 4 cycles. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will either continue to receive the chemotherapy or cross over to amivantamab in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment.

    Drug: Carboplatin · Drug: Pemetrexed

Interventions

  • Amivantamab will be administered as an IV infusion at a dose of 1400 mg (1750 mg if body weight is \>=80 kilogram \[kg\]) by once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is \>=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3 and will continue the same treatment in OLE phase then in LTE phase.

    Also known as: JNJ-61186372

  • Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm A and will continue the same treatment in OLE phase then in LTE phase.

  • Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle.

  • Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm B and will continue the same treatment in OLE phase then in LTE phase.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)

    PFS was defined as the time from randomization until the date of objective disease progression based on BICR using RECIST version 1.1 or death (by any cause) in the absence of progression, whichever came first. Participants who have not progressed or have not died at the time of analysis were censored at the time of the latest date of their last evaluable RECIST version 1.1 assessment. Pharmacodynamic: Sum of diameters increased by greater than or equal to (\>=)20 percent (%) and \>=5 millimeter (mm) from nadir (including baseline if it was smallest sum).

    Time frame: From randomization to either disease progression or death whichever occurs first (up to 29 months)

Secondary outcomes

  1. Objective Response Rate (ORR)

    Time frame: Up to 5 years 3 months

  2. Duration of Response (DoR)

    Time frame: Up to 5 years 3 months

  3. Overall Survival (OS)

    Time frame: Up to 5 years 3 months

  4. Time to Subsequent Therapy (TST)

    Time frame: Up to 5 years 3 months

  5. Progression-Free Survival After First Subsequent Therapy (PFS2)

    Time frame: Up to 5 years 3 months

  6. Time to Symptomatic Progression (TTSP)

    Time frame: Up to 5 years 3 months

  7. Number of Participants Treatment-emergent Adverse Events (TEAEs)

    Time frame: From Day 1 to 5 years 2 months

  8. Number of Participants TEAEs With Severity

    Time frame: From Day 1 to 5 years 2 months

  9. Number of Participants With Clinical Laboratory Abnormalities

    Time frame: Up to 5 years 3 months

  10. Number of Participants With Vital Signs Abnormalities

    Time frame: Up to 5 years 3 months

  11. Number of Participants With Physical Examination Abnormalities

    Time frame: Up to 5 years 3 months

  12. Serum Concentration of Amivantamab

    Time frame: Day 1 (Cycles 1, 2, 3, 5, 7, 9, 11, 13), Day 2 (Cycle 1)

  13. Number of Participants With Anti-Amivantamab Antibodies

    Time frame: Day 1 (Cycles 1, 2, 3, 5, 7, 9, 11, 13), Day 2 (Cycle 1)

  14. Change From Baseline in European Organization of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)

    Time frame: From baseline to 5 years 3 months

  15. Change From Baseline in Patient Reported Outcomes Measurement Information System-Physical Function (PROMIS-PF)

    Time frame: From baseline to 5 years 3 months

07

Results

Posted May 29, 2024

Participant flow

Participant flow — Overall Study
MilestoneArm B: Chemotherapy AloneArm A: Amivantamab + Chemotherapy
Started155153
Treated155151
Completed4228
Not completed113125
Withdrew: Withdrawal by subject59
Withdrew: Lost to follow-up21
Withdrew: Ongoing106115

Outcome measures

PrimaryProgression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)

PFS was defined as the time from randomization until the date of objective disease progression based on BICR using RECIST version 1.1 or death (by any cause) in the absence of progression, whichever came first. Participants who have not progressed or have not died at the time of analysis were censored at the time of the latest date of their last evaluable RECIST version 1.1 assessment. Pharmacodynamic: Sum of diameters increased by greater than or equal to (\>=)20 percent (%) and \>=5 millimeter (mm) from nadir (including baseline if it was smallest sum).

Time frame:
From randomization to either disease progression or death whichever occurs first (up to 29 months)
Reported as:
Median · Months
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
MonthsArm B: Chemotherapy AloneArm A: Amivantamab + Chemotherapy
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)6.70 (5.59 to 7.33)11.37 (9.79 to 13.70)
Statistical analysis
  • Arm B: Chemotherapy Alone vs Arm A: Amivantamab + Chemotherapy · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.395 · 95% CI 0.296 to 0.528
SecondaryObjective Response Rate (ORR)
Time frame:
Up to 5 years 3 months

Results for this outcome have not been posted.

SecondaryDuration of Response (DoR)
Time frame:
Up to 5 years 3 months

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)
Time frame:
Up to 5 years 3 months

Results for this outcome have not been posted.

SecondaryTime to Subsequent Therapy (TST)
Time frame:
Up to 5 years 3 months

Results for this outcome have not been posted.

SecondaryProgression-Free Survival After First Subsequent Therapy (PFS2)
Time frame:
Up to 5 years 3 months

Results for this outcome have not been posted.

SecondaryTime to Symptomatic Progression (TTSP)
Time frame:
Up to 5 years 3 months

Results for this outcome have not been posted.

SecondaryNumber of Participants Treatment-emergent Adverse Events (TEAEs)
Time frame:
From Day 1 to 5 years 2 months

Results for this outcome have not been posted.

SecondaryNumber of Participants TEAEs With Severity
Time frame:
From Day 1 to 5 years 2 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Clinical Laboratory Abnormalities
Time frame:
Up to 5 years 3 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Vital Signs Abnormalities
Time frame:
Up to 5 years 3 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Physical Examination Abnormalities
Time frame:
Up to 5 years 3 months

Results for this outcome have not been posted.

SecondarySerum Concentration of Amivantamab
Time frame:
Day 1 (Cycles 1, 2, 3, 5, 7, 9, 11, 13), Day 2 (Cycle 1)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Anti-Amivantamab Antibodies
Time frame:
Day 1 (Cycles 1, 2, 3, 5, 7, 9, 11, 13), Day 2 (Cycle 1)

Results for this outcome have not been posted.

SecondaryChange From Baseline in European Organization of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)
Time frame:
From baseline to 5 years 3 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Patient Reported Outcomes Measurement Information System-Physical Function (PROMIS-PF)
Time frame:
From baseline to 5 years 3 months

Results for this outcome have not been posted.

Adverse events

Collected over From baseline (Day 1 of Cycle 1) up to 29 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm B: Chemotherapy Alone42/155 (27.1%)48/155 (31%)149/155 (96.1%)
Arm A: Amivantamab + Chemotherapy28/151 (18.5%)56/151 (37.1%)151/151 (100%)
Most frequent serious events
Showing 10 of 87
Most frequent serious events
EventArm B: Chemotherapy AloneArm A: Amivantamab + Chemotherapy
PneumoniaInfections and infestations4/1556/151
AnaemiaBlood and lymphatic system disorders6/1551/151
DyspnoeaRespiratory, thoracic and mediastinal disorders5/1551/151
Pleural EffusionRespiratory, thoracic and mediastinal disorders5/1551/151
ThrombocytopeniaBlood and lymphatic system disorders5/1553/151
PneumonitisRespiratory, thoracic and mediastinal disorders0/1554/151
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders4/1554/151
Covid-19Infections and infestations1/1553/151
VomitingGastrointestinal disorders1/1553/151
HypokalaemiaMetabolism and nutrition disorders1/1553/151
Most frequent other events
Showing 10 of 68
Most frequent other events
EventArm B: Chemotherapy AloneArm A: Amivantamab + Chemotherapy
NeutropeniaBlood and lymphatic system disorders70/15588/151
ParonychiaInfections and infestations0/15585/151
AnaemiaBlood and lymphatic system disorders84/15576/151
RashSkin and subcutaneous tissue disorders12/15581/151
NauseaGastrointestinal disorders65/15555/151
Infusion Related ReactionInjury, poisoning and procedural complications2/15563/151
HypoalbuminaemiaMetabolism and nutrition disorders15/15562/151
ConstipationGastrointestinal disorders47/15560/151
LeukopeniaBlood and lymphatic system disorders50/15556/151
ThrombocytopeniaBlood and lymphatic system disorders46/15555/151

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm B: Chemotherapy AloneArm A: Amivantamab + ChemotherapyTotal
Mean60 ± 12.0159.3 ± 11.9259.6 ± 11.95
Sex: Female, Male
Sex: Female, Male(Participants)Arm B: Chemotherapy AloneArm A: Amivantamab + ChemotherapyTotal
Female9385178
Male6268130
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm B: Chemotherapy AloneArm A: Amivantamab + ChemotherapyTotal
Hispanic or Latino91322
Not Hispanic or Latino145137282
Unknown or Not Reported134
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm B: Chemotherapy AloneArm A: Amivantamab + ChemotherapyTotal
American Indian or Alaska Native213
Asian8997186
Native Hawaiian or Other Pacific Islander000
Black or African American022
White6049109
More than one race011
Unknown or Not Reported437
Region of Enrollment
Region of Enrollment(Participants)Arm B: Chemotherapy AloneArm A: Amivantamab + ChemotherapyTotal
AUSTRALIA426
BELGIUM123
BRAZIL5611
CANADA358
CHINA483987
FRANCE437
GERMANY202
HUNGARY011
INDIA6511
ISRAEL213
ITALY5712
JAPAN151934
MALAYSIA11011
MEXICO213
POLAND246
PORTUGAL314
RUSSIAN FEDERATION303
SOUTH KOREA101323
SPAIN131629
TAIWAN549
THAILAND022
TURKEY10313
UNITED KINGDOM314
UNITED STATES8816
08

Study locations

232 sites

Showing the first 100 of 232 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Tang K, Wu F, Yang F, Yao Y, Zhao Y, Zhou J, Sun P, Wang D, Lv D, Wang H, Hu Y, Li Q, Song Y, Gao G, Pan F, Bhattacharya A, Baig M, Lorenzini PA, Wortman-Vayn H, Agrawal T, Zhou C. Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial. Chin Med J (Engl). 2026 May 26. doi: 10.1097/CM9.0000000000004134. Online ahead of print. PubMed 42192224 ↗
  • Zhou C, Tang KJ, Liu B, Kim SW, Kitazono S, Ono A, Thiagarajan M, Hung JY, Boyer M, CIl T, Yao Y, Nagarkar R, Xie J, Bhattacharya A, Wortman-Vayn H, Baig M, Agrawal T, Lorenzini P, Lee SH, Cho BC. Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis. Lung Cancer. 2026 Mar;213:109302. doi: 10.1016/j.lungcan.2026.109302. Epub 2026 Feb 2. PubMed 41671628 ↗
  • Sanborn RE, Zhou C, Tang KJ, Cho BC, Cheng S, Popat S, Ono A, Lu S, Majem M, Aguilar A, Del Rosario Garcia Campelo M, Hayashi H, Lee KY, Lee SH, Delmonte A, Alatorre-Alexander J, Richardson G, Santos V, Dooms C, Sabari JK, Shu CA, Girard N, Mansfield AS, Park K, Xia Y, Bhattacharya A, Buyukkaramikli N, Perualila N, Diels J, Acharya S, Chandler C, Proskorovsky I, Dearden L, Wortman-Vayn H, Mahadevia PJ, Knoblauch RE, Agrawal T, Baig M, Felip E. Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study. Target Oncol. 2025 Nov;20(6):979-989. doi: 10.1007/s11523-025-01182-0. Epub 2025 Nov 3. PubMed 41184595 ↗
  • Kitazono S, Ono A, Kawamura T, Hataji O, Tanaka H, Matsumoto S, Watanabe N, Nagashima H, Oki M, Takahashi M, Anazawa T, Shirai T, Yamashita A, Wortman-Vayn H, Bhattacharya A, Agrawal T, Baig M, Knoblauch RE, Hayashi H. Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC. Cancer Sci. 2025 Nov;116(11):3139-3148. doi: 10.1111/cas.70180. Epub 2025 Sep 8. PubMed 40922529 ↗
  • Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourao Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441. Epub 2023 Oct 21. PubMed 37870976 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in May 2023, 30 months.

Results were first posted in May 2024, 1 year after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 30 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2027 → Dec 2027, on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2020
First posted
Sep 4, 2020
StartActual
Oct 13, 2020
Primary completionActual
May 3, 2023
CompletionEst.
Dec 31, 2027was Aug 2027
Results first posted
May 29, 2024
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Moscow City Oncology Hospital No 62 · Krasnogorsk, Russia
Show 1 removed
  • Moscow City Oncology Hospital № 62 · Krasnogorsk, Russia
Oct 29, 2026
Study completion
Aug 2, 2027→Dec 31, 2027
Oct 29, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 2 other changes: verification date and site details
  2. Oct 29, 2026
    1 site added, 1 site removed
    Show site
    • Moscow City Oncology Hospital No 62 · Krasnogorsk, Russia
    Show 1 removed
    • Moscow City Oncology Hospital № 62 · Krasnogorsk, Russia
    Study completion Aug 2, 2027→Dec 31, 2027
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04538664
Responsible party
Sponsor
First posted
Sep 4, 2020
Start date
Oct 13, 2020
Primary completion
May 3, 2023
Completion
Dec 31, 2027 (estimated)
Results posted
May 29, 2024
Last update
Nov 3, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Carboplatin

Start the discussion